edecrin etacrynic acid 25 mg tablet bottle
a menarini australia pty ltd - etacrynic acid -
edecril
merck sharp & dohme (new zealand) limited - etacrynic acid 50mg - tablet - 50 mg - active: etacrynic acid 50mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate maize starch purified talc
vpi-ethacrynate sodium powder for solution
vpi pharmaceuticals inc - ethacrynic acid (ethacrynate sodium) - powder for solution - 50mg - ethacrynic acid (ethacrynate sodium) 50mg - loop diuretics
ethacrynate sodium for injection usp powder for solution
sterimax inc - ethacrynic acid (ethacrynate sodium) - powder for solution - 50mg - ethacrynic acid (ethacrynate sodium) 50mg - loop diuretics
ethacrynate sodium for injection powder for solution
endo par innovation company, llc - ethacrynic acid (ethacrynate sodium) - powder for solution - 50mg - ethacrynic acid (ethacrynate sodium) 50mg - loop diuretics
sodium edecrin powder for solution
bausch health, canada inc. - ethacrynic acid (ethacrynate sodium) - powder for solution - 50mg - ethacrynic acid (ethacrynate sodium) 50mg - loop diuretics
edecrin tablet
bausch health, canada inc. - ethacrynic acid - tablet - 25mg - ethacrynic acid 25mg - loop diuretics
vancomycin juno vancomycin (as hydrochloride) 1 g powder for injection vial
juno pharmaceuticals pty ltd - vancomycin hydrochloride, quantity: 952 mg (equivalent: vancomycin, qty 1000000 iu) - injection, powder for - excipient ingredients: sodium hydroxide; hydrochloric acid - vancomycin juno is indicated in potentially life-threatening infections which cannot be treated with another effective, less toxic antimicrobial drug, including the penicillins and cephalosporins.,vancomycin juno is useful in therapy of severe staphylococcal (including methicillin-resistant staphylococcal) infections in patients who cannot receive or who failed to respond to the penicillins and cephalosporins or who have infections with staphylococci that are resistant to other antibiotics. once sensitivity data are available, therapy should be adjusted accordingly.,vancomycin juno is effective alone or in combination with an aminoglycoside for endocarditis caused by s. viridans or s. bovis. for endocarditis caused by enterococci (e.g. e. faecalis), vancomycin juno is effective only in combination with an aminoglycoside. vancomycin juno is effective for the treatment of diphtheroid endocarditis. vancomycin juno is used in combination with rifampin, an aminoglycoside, or both in early-onset prosthetic valve en
vancomycin juno vancomycin (as hydrochloride) 500 mg powder for injection vial
juno pharmaceuticals pty ltd - vancomycin hydrochloride, quantity: 476 mg (equivalent: vancomycin, qty 500000 iu) - injection, powder for - excipient ingredients: hydrochloric acid; sodium hydroxide - vancomycin juno is indicated in potentially life-threatening infections which cannot be treated with another effective, less toxic antimicrobial drug, including the penicillins and cephalosporins.,vancomycin juno is useful in therapy of severe staphylococcal (including methicillin-resistant staphylococcal) infections in patients who cannot receive or who failed to respond to the penicillins and cephalosporins or who have infections with staphylococci that are resistant to other antibiotics. once sensitivity data are available, therapy should be adjusted accordingly.,vancomycin juno is effective alone or in combination with an aminoglycoside for endocarditis caused by s. viridans or s. bovis. for endocarditis caused by enterococci (e.g. e. faecalis), vancomycin juno is effective only in combination with an aminoglycoside. vancomycin juno is effective for the treatment of diphtheroid endocarditis. vancomycin juno is used in combination with rifampin, an aminoglycoside, or both in early-onset prosthetic valve en
vancomycin baxter vancomycin (as hydrochloride) 1 g powder for injection vial
baxter healthcare pty ltd - vancomycin hydrochloride, quantity: 1025.2 mg - injection, powder for - excipient ingredients: hydrochloric acid; sodium hydroxide - vancomycin baxter is indicated for potentially life threatening infections which cannot be treated with another effective, less toxic antimicrobial drug, including the penicillins and cephalosporins.,vancomycin baxter is useful in therapy of severe staphylococcal (including methicillin-resistant staphylococcal) infections in patients who cannot receive or who have failed to respond to the penicillins and cephalosporins or who have infections with staphylococci that are resistant to other antibiotics. once sensitivity data are available, therapy should be adjusted accordingly.,vancomycin baxter is effective alone or in combination with an aminoglycoside for endocarditis caused by s. viridans or s. bovis. for endocarditis caused by enterococci (e.g., s. faecalis), vancomycin is effective only in combination with an aminoglycoside. vancomycin is effective for the treatment of diphtheroid endocarditis. vancomycin baxter is used in combination with rifampicin, an aminoglycoside, or both in early onset prosthetic v